WO2005082371A2 - Composition amaigrissante par voie orale comprenant de l’acide linoleique conjugue et de la cafeine - Google Patents
Composition amaigrissante par voie orale comprenant de l’acide linoleique conjugue et de la cafeine Download PDFInfo
- Publication number
- WO2005082371A2 WO2005082371A2 PCT/FR2005/000166 FR2005000166W WO2005082371A2 WO 2005082371 A2 WO2005082371 A2 WO 2005082371A2 FR 2005000166 W FR2005000166 W FR 2005000166W WO 2005082371 A2 WO2005082371 A2 WO 2005082371A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- caffeine
- composition according
- composition
- linoleic acid
- conjugated linoleic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Definitions
- the present invention relates to a slimming composition for oral administration comprising a combination of conjugated linoleic acid and caffeine as active ingredient.
- Conjugated linoleic acid is a mixture of linoleic acid isomers that are found naturally in milk and milk products, as well as in the meat of ruminants.
- the term CLA includes all of the configuration and position isomers of octadecadienoic acid (Cl 8: 2), in particular the cis and trans form of the 9,11-, 10,12- and 11,13-octadecadienoic acids. .
- CLA body fat
- body mass muscle
- the effective dose is 1 to 2 g / day.
- CLA modifies the metabolism of lipids and in particular reduces their storage in the form of fats.
- CLA increases the body's energy expenditure (or thermogenesis) and thus promotes the use of reserve fats as an energy source.
- Caffeine is an alkaloid found in many plants, especially in coffee beans, tea leaves or kolatier seeds. Besides its stimulating psychic and diuretic activity, caffeine is also known as an agent stimulating thermogenesis and therefore as an oral slimming agent.
- the subject of the present invention is a slimming composition for oral administration comprising: - a combination of conjugated linoleic acid and caffeine as active ingredient, and - an acceptable support for oral administration.
- the invention relates more particularly to a slimming composition for oral administration comprising: a combination of conjugated linoleic acid and caffeine as active ingredient with a mass ratio of conjugated linoleic acid / caffeine of between 1 and 15, preferably between 1 and 6, and - an acceptable support for oral administration.
- the acceptable support for oral administration can be any physiologically acceptable substance, liquid, solid or pasty, more or less inert, in which said active ingredient is incorporated in order to facilitate the preparation as well as the oral administration and condition its consistency, shape and volume.
- This support can in particular be a food support.
- said composition can advantageously be in the form of soluble coffee, that is to say atomized or lyophilized coffee, powder, soluble in water, obtained exclusively from roasted coffee by physical methods using water as the only entrainer not from coffee.
- the most common source of caffeine is coffee which is generally consumed in the form of a drink.
- the caffeine content can vary greatly depending on the type of coffee or the method of preparation.
- the table below still gives an approximate order of magnitude for a 237 ml cup. This table also shows that caffeine can come from other drinks such as tea or cola-based carbonated drinks, but that their caffeine content is lower than that of coffee.
- Caffeine can stimulate thermogenesis, but only at high doses, especially at doses above 600 mg / day. However, at high doses, caffeine can cause adverse effects such as insomnia, irritability, tachycardia or hypertension, or even be toxic. If we associate CLA with caffeine, then we reduce the daily dose necessary to obtain a weight loss effect or for the same daily dose, we increase the weight loss effect of coffee. However, CLA is in the form of an oil which is very difficult to disperse in water. If CLA is added to liquid coffee, drops of oil will form on the surface of the liquid, which is not satisfactory for the consumer.
- the CLA can be combined with lecithin and colloidal silica.
- lecithin and colloidal silica make it possible to prepare CLA in the form of a powder which disperses perfectly in an aqueous medium.
- Said composition can therefore be in the form of powder, tablets, capsules, capsules or powdered sachets.
- Said composition advantageously contains lecithin and colloidal silica to allow good dispersion of the CLA in an aqueous medium.
- Said composition may also contain other active principles which help to limit the level of carbohydrates in the blood, such as a green coffee extract preferably containing from 5 to 10% by weight of caffeine, and / or chromium chloride .
- Said composition can be used as a food supplement, dietetic composition or cosmetic composition, in particular for increasing weight loss, as part of an aesthetic treatment aimed at improving the silhouette of a person.
- Said composition can also be used as a medicament, in particular intended for treating or preventing obesity.
- the therapeutic objective in obesity is defined as follows: it is either to allow the subject to lose weight significantly, or to help the subject to keep the weight level as low as possible.
- the effective dose to increase weight loss is at least 60 mg of caffeine and 300 mg of CLA, twice a day.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05717490A EP1708716B1 (fr) | 2004-01-27 | 2005-01-26 | Composition amaigrissante par voie orale comprenant de l'acide linoleique conjugue et de la cafeine |
US10/587,441 US20070269533A1 (en) | 2004-01-27 | 2005-01-26 | Oral Dieting Composition Comprising Conjugated Linoleic Acid and Caffeine |
DE602005001849T DE602005001849T2 (de) | 2004-01-27 | 2005-01-26 | Orale diätzusammensetzung, enthaltend konjugierte linolsäure und coffein |
DK05717490T DK1708716T3 (da) | 2004-01-27 | 2005-01-26 | Oralt slankepræparat som omfatter konjugeret linolsyre og coffein |
CA002554435A CA2554435A1 (fr) | 2004-01-27 | 2005-01-26 | Composition amaigrissante par voie orale comprenant de l'acide linoleique conjugue et de la cafeine |
US12/580,879 US20100041679A1 (en) | 2004-01-27 | 2009-10-16 | Oral dieting composition comprising conjugated linoleic acid and caffeine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0400739 | 2004-01-27 | ||
FR0400739A FR2865402B1 (fr) | 2004-01-27 | 2004-01-27 | Composition amaigrissante par voie orale comprenant de l'acide linoleique conjugue et de la cafeine. |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/580,879 Continuation US20100041679A1 (en) | 2004-01-27 | 2009-10-16 | Oral dieting composition comprising conjugated linoleic acid and caffeine |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005082371A2 true WO2005082371A2 (fr) | 2005-09-09 |
WO2005082371A3 WO2005082371A3 (fr) | 2006-01-05 |
Family
ID=34717436
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2005/000166 WO2005082371A2 (fr) | 2004-01-27 | 2005-01-26 | Composition amaigrissante par voie orale comprenant de l’acide linoleique conjugue et de la cafeine |
Country Status (10)
Country | Link |
---|---|
US (2) | US20070269533A1 (fr) |
EP (1) | EP1708716B1 (fr) |
AT (1) | ATE368465T1 (fr) |
CA (1) | CA2554435A1 (fr) |
DE (1) | DE602005001849T2 (fr) |
DK (1) | DK1708716T3 (fr) |
ES (1) | ES2288296T3 (fr) |
FR (1) | FR2865402B1 (fr) |
PT (1) | PT1708716E (fr) |
WO (1) | WO2005082371A2 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006079056A1 (fr) * | 2005-01-20 | 2006-07-27 | Stephen Holt | Compositions vegetales a base d'hoodia |
PT2484345E (pt) * | 2005-11-04 | 2014-05-15 | Inqpharm Group Sdn Bhd | Composição herbal para gestão do peso |
US20090246326A1 (en) * | 2008-03-25 | 2009-10-01 | Empty Nest Ideas, Llc | Coffee product and method |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001017498A1 (fr) * | 1999-09-09 | 2001-03-15 | Pentapharm Ltd. | Utilisation d'acide linoleique conjugue pour le traitement topique de la cellulite |
WO2001060331A2 (fr) * | 2000-02-15 | 2001-08-23 | Zen-Bio, Inc. | Compositions destinees a prevenir la cellulite chez un mammifere |
US6413545B1 (en) * | 1998-09-01 | 2002-07-02 | Access Business Group International Llc | Diet composition and method of weight management |
-
2004
- 2004-01-27 FR FR0400739A patent/FR2865402B1/fr not_active Expired - Fee Related
-
2005
- 2005-01-26 ES ES05717490T patent/ES2288296T3/es active Active
- 2005-01-26 CA CA002554435A patent/CA2554435A1/fr not_active Abandoned
- 2005-01-26 PT PT05717490T patent/PT1708716E/pt unknown
- 2005-01-26 WO PCT/FR2005/000166 patent/WO2005082371A2/fr active IP Right Grant
- 2005-01-26 DK DK05717490T patent/DK1708716T3/da active
- 2005-01-26 DE DE602005001849T patent/DE602005001849T2/de active Active
- 2005-01-26 AT AT05717490T patent/ATE368465T1/de active
- 2005-01-26 US US10/587,441 patent/US20070269533A1/en not_active Abandoned
- 2005-01-26 EP EP05717490A patent/EP1708716B1/fr not_active Not-in-force
-
2009
- 2009-10-16 US US12/580,879 patent/US20100041679A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6413545B1 (en) * | 1998-09-01 | 2002-07-02 | Access Business Group International Llc | Diet composition and method of weight management |
WO2001017498A1 (fr) * | 1999-09-09 | 2001-03-15 | Pentapharm Ltd. | Utilisation d'acide linoleique conjugue pour le traitement topique de la cellulite |
WO2001060331A2 (fr) * | 2000-02-15 | 2001-08-23 | Zen-Bio, Inc. | Compositions destinees a prevenir la cellulite chez un mammifere |
Also Published As
Publication number | Publication date |
---|---|
EP1708716A2 (fr) | 2006-10-11 |
DE602005001849T2 (de) | 2007-12-13 |
US20070269533A1 (en) | 2007-11-22 |
DK1708716T3 (da) | 2007-10-08 |
PT1708716E (pt) | 2007-10-02 |
EP1708716B1 (fr) | 2007-08-01 |
DE602005001849D1 (de) | 2007-09-13 |
FR2865402B1 (fr) | 2006-04-28 |
ES2288296T3 (es) | 2008-01-01 |
CA2554435A1 (fr) | 2005-09-09 |
ATE368465T1 (de) | 2007-08-15 |
WO2005082371A3 (fr) | 2006-01-05 |
US20100041679A1 (en) | 2010-02-18 |
FR2865402A1 (fr) | 2005-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5932624A (en) | Vitamin supplement composition | |
US20180104299A1 (en) | Use of saffron and/or safranal and/or crocin and/or picrocrocin and/or derivatives thereof as a satiation agent for the treatment of obesity | |
US8597692B2 (en) | Cocoa extract and use thereof | |
JP2002053464A (ja) | 高血圧症予防・治療剤 | |
FR2981545A1 (fr) | Produit dietetique destine a la diminution de la graisse viscerale en preoperatoire bariatrique | |
JP4077149B2 (ja) | 自律神経機能向上剤 | |
EP1708716B1 (fr) | Composition amaigrissante par voie orale comprenant de l'acide linoleique conjugue et de la cafeine | |
CN101001543A (zh) | 硫辛酸浓缩物 | |
EP3027064B1 (fr) | Composition pharmaceutique, diététique ou alimentaire liquide ou semi-liquide dépourvue d'amertume contenant un sel d'arginine | |
WO2001093855A1 (fr) | Compositions et aliments hydratants | |
JP5602696B2 (ja) | プロアントシアニジンによる性的機能及び性器血管系の改善 | |
JP4210364B2 (ja) | 自律神経機能向上剤及び食品 | |
BE1026122A1 (fr) | Composition pour prévenir ou réduire les effets d'une intoxication alcoolique | |
KR20190050016A (ko) | 오메가-3을 유효성분으로 포함하는 안구 건조증의 예방 또는 개선용 건강 기능성 식품조성물 | |
FR2849601A1 (fr) | Nouvelles compositions synergiques de boissons stimulant le metabolisme cellulaire pour ameliorer l'efficacite des extraits de plantes | |
JP2003261445A (ja) | 血中中性脂肪低減剤 | |
EP1598063A1 (fr) | Compositions synergiques de vitamines, de minéraux et d'oligo-éléments pour stimuler l'élimination des lipides intracellulaires | |
FR2989557A1 (fr) | Nouvelles compositions alimentaires et leur mode de realisation | |
BE1021980B1 (fr) | Composition amincissante. | |
FR3015860B1 (fr) | Composition alimentaire de regime pour diminuer l'inflammation de bas grade a court et long terme comprenant de l'acide docosahexaenoique | |
FR2929120A1 (fr) | Composition ayant une activite d'amincissement corporel et/ou diuretique chez les mammiferes | |
JP2022059811A (ja) | 桂皮酸誘導体の吸収促進剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2554435 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005717490 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005717490 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10587441 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 2005717490 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10587441 Country of ref document: US |